精密ターゲティング,炎症調節,プラーク安定化

Yunqi Zhang¹, Feifei Li², Libo Liu¹

¹Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, P. R. China.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

|August 28, 2025

まとめ

ナノ粒子薬剤投与システム (NDDS) は,病変を標的とし,プラークの微小環境に反応することによって,高度な動脈硬化症の治療を提供します. これらのシステムは従来の方法と比較して効果を高め副作用を軽減します

科学分野:

心血管医学
生物医学工学
ナノテクノロジー

背景:

動脈硬化症は複雑な病原性を持つ心臓血管疾患の主要な原因です.
現在の治療法は病気の多面性により限界に直面しています

研究の目的:

動脈硬化症の病理学的メカニズムを見直す
動脈硬化症の治療のためのナノ粒子薬物投与システム (NDDS) の進歩を検証する.

主な方法:

病理学的メカニズムを体系的に検討する.
標的型動脈硬化症の治療のためのNDDSの最近の発展の分析.

主要な成果:

NDDSは動脈硬化症の進行に関わる細胞活動を調節することができます.
標的型投与と刺激反応性放出により,治療効果が向上する.
NDDSは全身的な有害な効果を最小限に抑えます

結論:

NDDSは,動脈硬化症の伝統的な薬学的治療の限界を克服します.
NDDSを使用したパーソナライズされた介入は,疾患の進行を弱め,プラークを安定させ,回復を促進することができます.
NDDSは,動脈硬化症の治療パラダイムを再定義し,患者のアウトカムを改善する変革の可能性を持っています.

キーワード:

動脈硬化症薬物の配達ナノ医療ナノ粒子

さらに関連する動画

08:13

Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis

Published on: March 22, 2016

10.6K

10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

7.7K

関連する概念動画

01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

644

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Inflammation

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...

関連する実験動画